Premature Ejaculation Disorder Therapeutics Market in US 2021-2025
SKU ID : TNV-17793483 | Publishing Date : 10-Mar-2021 | No. of pages : 120
Detailed TOC of Premature Ejaculation Disorder Therapeutics Market in US 2021-2025
• Executive Summaryo Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Route of Administration
o Market segments
o Comparison by Route of Administration
o Oral - Market size and forecast 2020-2025
o Topical - Market size and forecast 2020-2025
o Market opportunity by Route of Administration
• Market Segmentation by Drug Class
o Market segments
o Comparison by Drug Class
o SSRIs - Market size and forecast 2020-2025
o PDE5 inhibitors - Market size and forecast 2020-2025
o Amide anesthetics - Market size and forecast 2020-2025
o Others - Market size and forecast 2020-2025
o Market opportunity by Drug Class
• Customer Landscape
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Absorption Pharmaceuticals LLC
o Alembic Pharmaceuticals Inc.
o Amneal Pharmaceuticals Inc.
o Bayer AG
o Eli Lilly and Co.
o InvaGen Pharmaceuticals Inc.
o Pfizer Inc.
o Sandoz AG
o Solco Healthcare
o Teva Pharmaceutical Industries Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 5
• 4: Key Finding 6
• 5: Key Finding 7
• 6: Parent market
• 7: Market characteristics
• 8: Offerings of vendors included in the market definition
• 9: Market segments
• 10: Global - Market size and forecast 2020 - 2025 ($ million)
• 11: Global market: Year-over-year growth 2020 - 2025 (%)
• 12: Five forces analysis 2020 & 2025
• 13: Bargaining power of buyers
• 14: Bargaining power of suppliers
• 15: Threat of new entrants
• 16: Threat of substitutes
• 17: Threat of rivalry
• 18: Market condition - Five forces 2020
• 19: Other1 - Market share 2020-2025 (%)
• 20: Comparison by Other1
• 21: Oral - Market size and forecast 2020-2025 ($ million)
• 22: Oral - Year-over-year growth 2020-2025 (%)
• 23: Topical - Market size and forecast 2020-2025 ($ million)
• 24: Topical - Year-over-year growth 2020-2025 (%)
• 25: Market opportunity by Other1
• 26: Other2 - Market share 2020-2025 (%)
• 27: Comparison by Other2
• 28: SSRIs - Market size and forecast 2020-2025 ($ million)
• 29: SSRIs - Year-over-year growth 2020-2025 (%)
• 30: PDE5 inhibitors - Market size and forecast 2020-2025 ($ million)
• 31: PDE5 inhibitors - Year-over-year growth 2020-2025 (%)
• 32: Amide anesthetics - Market size and forecast 2020-2025 ($ million)
• 33: Amide anesthetics - Year-over-year growth 2020-2025 (%)
• 34: Others - Market size and forecast 2020-2025 ($ million)
• 35: Others - Year-over-year growth 2020-2025 (%)
• 36: Market opportunity by Other2
• 37: Customer landscape
• 38: Impact of drivers and challenges
• 39: Vendor landscape
• 40: Landscape disruption
• 41: Industry risks
• 42: Vendors covered
• 43: Market positioning of vendors
• 44: Absorption Pharmaceuticals LLC - Overview
• 45: Absorption Pharmaceuticals LLC - Product and service
• 46: Absorption Pharmaceuticals LLC - Key offerings
• 47: Absorption Pharmaceuticals LLC - Key customers
• 48: Absorption Pharmaceuticals LLC - Segment focus
• 49: Alembic Pharmaceuticals Inc. - Overview
• 50: Alembic Pharmaceuticals Inc. - Product and service
• 51: Alembic Pharmaceuticals Inc. - Key offerings
• 52: Alembic Pharmaceuticals Inc. - Key customers
• 53: Alembic Pharmaceuticals Inc. - Segment focus
• 54: Amneal Pharmaceuticals Inc. - Overview
• 55: Amneal Pharmaceuticals Inc. - Business segments
• 56: Amneal Pharmaceuticals Inc. - Key offerings
• 57: Amneal Pharmaceuticals Inc. - Key customers
• 58: Amneal Pharmaceuticals Inc. - Segment focus
• 59: Bayer AG - Overview
• 60: Bayer AG - Business segments
• 61: Bayer AG - Key offerings
• 62: Bayer AG - Key customers
• 63: Bayer AG - Segment focus
• 64: Eli Lilly and Co. - Overview
• 65: Eli Lilly and Co. - Business segments
• 66: Eli Lilly and Co. - Key offerings
• 67: Eli Lilly and Co. - Key customers
• 68: Eli Lilly and Co. - Segment focus
• 69: InvaGen Pharmaceuticals Inc. - Overview
• 70: InvaGen Pharmaceuticals Inc. - Product and service
• 71: InvaGen Pharmaceuticals Inc. - Key offerings
• 72: InvaGen Pharmaceuticals Inc. - Key customers
• 73: InvaGen Pharmaceuticals Inc. - Segment focus
• 74: Pfizer Inc. - Overview
• 75: Pfizer Inc. - Business segments
• 76: Pfizer Inc. - Key offerings
• 77: Pfizer Inc. - Key customers
• 78: Pfizer Inc. - Segment focus
• 79: Sandoz AG - Overview
• 80: Sandoz AG - Product and service
• 81: Sandoz AG - Key offerings
• 82: Sandoz AG - Key customers
• 83: Sandoz AG - Segment focus
• 84: Solco Healthcare - Overview
• 85: Solco Healthcare - Product and service
• 86: Solco Healthcare - Key offerings
• 87: Solco Healthcare - Key customers
• 88: Solco Healthcare - Segment focus
• 89: Teva Pharmaceutical Industries Ltd. - Overview
• 90: Teva Pharmaceutical Industries Ltd. - Business segments
• 91: Teva Pharmaceutical Industries Ltd. - Key offerings
• 92: Teva Pharmaceutical Industries Ltd. - Key customers
• 93: Teva Pharmaceutical Industries Ltd. - Segment focus
• 94: Currency conversion rates for US$
• 95: Research Methodology
• 96: Validation techniques employed for market sizing
• 97: Information sources
• 98: List of abbreviations